Authors
Junxia Sun, Zhiwei Lu, Hongliang Li, Sufang Qiu
Published in
Clinical immunology (Orlando, Fla.). Pages 110791. Nov 12, 2026. Epub Nov 12, 2026.
Abstract
Nasopharyngeal carcinoma (NPC) shows distinct distribution, and immunotherapy efficacy is limited by T cell dysfunction. Galectin-9 (LGALS9) has immunomodulatory roles, but its mechanism in NPC immune evasion remains unclear.
Using scRNA-seq data from GEO, we analyzed the NPC immune microenvironment and identified key ligand-receptor pairs. LGALS9 and CD44 expression were validated by immunohistochemistry, RT-qPCR, and western blot. CD8+ T cell function was assessed by flow cytometry, ELISA, and LDH release assay. The association between LGALS9 and CD44 was examined by coimmunoprecipitation, and a mouse model evaluated LGALS9 knockdown and CD44 antibody treatment.
LGALS9 was upregulated in NPC and negatively correlated with CD8+ T cell infiltration. The LGALS9-CD44 association suppressed CD8+ T cell proliferation and activation, increasing PD1+ cells, decreasing GZMB+ cells and TNF-α/IFN-γ levels. Blocking this interaction restored T cell activity. LGALS9 knockdown inhibited tumor growth, and CD44 antibody blockade further potentiated the antitumor immune effect induced by LGALS9 knockdown.
LGALS9 promotes NPC immune evasion through its association with CD44 on CD8+ T cells in vitro, and in vivo CD44 blockade is consistent with this mechanism, providing a rationale for targeting the LGALS9-CD44 axis.
PMID:
43020208
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0